{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzyme+Inhibitor+Therapy&page=2",
    "query": {
      "intervention": "Enzyme Inhibitor Therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzyme+Inhibitor+Therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T13:14:39.819Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00866879",
      "title": "Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Demographic Data, Medical History, and Donor Data",
          "type": "OTHER"
        },
        {
          "name": "Blood Draws for Control Group",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Draws for Experimental Group",
          "type": "PROCEDURE"
        },
        {
          "name": "Donor Blood Draws",
          "type": "PROCEDURE"
        },
        {
          "name": "Donor Information",
          "type": "OTHER"
        },
        {
          "name": "Kidney Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 275,
      "start_date": "2007-06",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-28",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00866879"
    },
    {
      "nct_id": "NCT03959891",
      "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Aromatase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2019-05-30",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959891"
    },
    {
      "nct_id": "NCT00001521",
      "title": "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia (CAH)"
      ],
      "interventions": [
        {
          "name": "Fludrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Testolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 66,
      "start_date": "1995-06-08",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001521"
    },
    {
      "nct_id": "NCT03178201",
      "title": "TGR1202 in Relapsed and Refractory Follicular Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "TGR-1202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2017-08-20",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03178201"
    },
    {
      "nct_id": "NCT01856361",
      "title": "Ramipril for the Treatment of Oligospermia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oligospermia",
        "Teratospermia",
        "Asthenozoospermia",
        "Male Infertility"
      ],
      "interventions": [
        {
          "name": "Ramipril",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2013-07",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01856361"
    },
    {
      "nct_id": "NCT01422486",
      "title": "Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "ezatiostat hydrochloride (Telintra®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2011-10",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 5,
      "location_summary": "Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422486"
    },
    {
      "nct_id": "NCT04369664",
      "title": "CHOlesterol Lowering and Residual Risk in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Statin",
          "type": "DRUG"
        },
        {
          "name": "PCSK9 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 10mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 151,
      "start_date": "2020-08-12",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04369664"
    },
    {
      "nct_id": "NCT05948969",
      "title": "Transform CV Risk in Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Decision support",
          "type": "OTHER"
        },
        {
          "name": "Facilitated referral to a cardiometabolic team-based center",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "American College of Cardiology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "2023-09-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05948969"
    },
    {
      "nct_id": "NCT05345717",
      "title": "Novel Desensitization Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "End Stage Kidney Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Belatacept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-05-01",
      "completion_date": "2025-09-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05345717"
    },
    {
      "nct_id": "NCT03008018",
      "title": "Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "KA2507",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karus Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-08-07",
      "completion_date": "2020-06-10",
      "has_results": false,
      "last_update_posted_date": "2020-08-19",
      "last_synced_at": "2026-09-29T13:14:39.819Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03008018"
    }
  ]
}